A Biopharmaceutical Study on Rifampicin-Polyvinylpyrrolidone Coprecipitate

Rifampicin-Polyvinylpyrrolidone 공침물에 관한 생물약제학적 연구

Rifampicin-polyvinylpyrrolidone coprecipitates were prepared by the solvent method to increase the solubility and dissolution rate, thereby improving absorption of rifampicin. It was found that the solubility and dissolution rate were greater with the 1 : 5 (w/w) coprecipitate than with the pure drug, physical mixtures or coprecipitates of any other ratio of the two components. The blood concentration data in non-fasted rats showed that the extent of absorption of rifampicin were significantly enhanced following the oral administration of the 1 : 5 coprecipitate; The area under the serum concentration curve (0-8hr) was 1.3 times greater with the 1 : 5 coprecipitate than with the pure drug. The blood concentration reached its peak (4. 38$\pm$1.36mcg/ml) within two hours in the case of oral administration of the 1 : 5 coprecipitate and, on the other hand, it reached the maximum (3.77$\pm$0.90mcg/ml) after four hours of oral administration of the pure drug. It was observed that there was no significant difference between the 1 : 5 coprecipitate and the pure drug in the extent and rate of absorption of rifampicin when fasted rats were used. When the 1 : 5 coprecipitate was orally administered to human subjects 20 minutes after meal, it was found that the blood concentration reached the maximum after one hour; in the case of the pure drug, it reached its peak after four hours.